Drugs / CKD-379
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06652971 | Nov → Dec 2024 | type 2 diabetes mellitus | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT05952219 | Jun 2023 | type 2 diabetes mellitus | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 1 | NCT05719155 | Feb → Mar 2023 | type 2 diabetes mellitus | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT05452525 | Jul → Aug 2022 | type 2 diabetes mellitus | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CKD-379 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05452525 ↗ |
| Route | Oral | “a single oral dose of 1 tablet under fasting condition” NCT06652971 ↗ |